Monitor for Q1 2026 revenue trends — if RenovoCath approaches $1.5M quarterly revenue, milestone warrants could trigger, signaling commercial traction. Watch for enrollment updates in the TIGeR-PaC trial as a key clinical catalyst.
Price Chart
Executive Summary
RenovoRx (RNXT) announced an oversubscribed private placement expected to raise approximately $10 million in gross proceeds through the sale of common stock and milestone-based warrants. The financing, led by life science institutional investors and including insider participation, aims to accelerate commercialization of its RenovoCath device and advance its Phase III TIGeR-PaC trial in pancreatic cancer toward full enrollment by mid-2026.
Key Financial Metrics
Key Facts
- Private placement expected to raise $10 million in gross proceeds
- Approximately 10.64 million shares (and pre-funded warrants) issued at $0.938 per share
- Milestone warrants issued for 5.32 million shares at $1.751 exercise price (100% premium)
- Warrants exercisable upon first quarter with $1.5M in gross product revenue or by March 30, 2029
- Executives and board members participated at higher price of $1.029 per share
- Proceeds to fund RenovoCath commercialization and Phase III TIGeR-PaC trial enrollment
- RenovoCath generated ~$900K in revenue over first nine months of 2025
Financial Impact
$10 million raised; ~10.64 million new shares issued, representing significant dilution; $900K in RenovoCath revenue through 9M 2025
Risk Factors
- Significant shareholder dilution from issuance of over 10.6 million shares
- Milestone revenue target ($1.5M/quarter) not yet achieved; current run rate implies ~$1.2M annualized
- Forward-looking statements dominate; no updated financials or clinical data provided
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3258176 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 22, 2026 5d ago | Press Release | $1.27 | awaiting T+60 | — | $1.41 (+11.02%) |
Jul 29, 2026 12w ago | Press Release | $0.8981 $1.27 | ▲ +41.41% | ▲ +36.68% | $1.41 (+57.00%) |
Jul 2, 2026 16w ago | 8-K | $0.9201 $1.68 | ▼ −82.59% | ▼ −79.58% | $1.41 (−53.24%) |
May 26, 2026 22w ago | Press Release | $0.9160 $1.32 | ▲ +43.56% | ▲ +40.83% | $1.41 (+53.93%) |
May 19, 2026 23w ago | Press Release | $0.8060 $1.26 | ▲ +56.33% | ▲ +50.04% | $1.41 (+74.94%) |
May 15, 2026 23w ago | 10-K/A | $0.7830 $1.12 | ▲ +43.04% | ▲ +38.19% | $1.41 (+80.08%) |
May 14, 2026 23w ago | 8-K | $0.8200 $1.15 | ▲ +40.24% | ▲ +35.73% | $1.41 (+71.95%) |
Apr 29, 2026 25w ago | Press Release | $0.8310 $0.8653 | ▲ +4.13% | ▲ +0.02% | $1.41 (+69.68%) |
Apr 28, 2026 26w ago | EFFECT | $0.8400 $0.8545 | ▲ +1.73% | ▼ −2.26% | $1.41 (+67.86%) |
Apr 16, 2026 27w ago | S-3 | $1.00 $0.8500 | ▼ −15.00% | ▼ −21.14% | $1.41 (+41.00%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers